Published on 23/12/2025

Demystifying Site Feasibility and Site Selection in Clinical Research

In clinical trial operations, “site feasibility” and “site selection” are often used interchangeably, yet they serve distinct purposes. Both processes are crucial during the study start-up phase, impacting timelines, recruitment, and regulatory compliance. This guide provides a step-by-step explanation of how site feasibility differs from site selection and how they interconnect in building an optimal trial site network.

Table of Contents

What Is Site Feasibility?

Site feasibility is the preliminary assessment of a site’s capability and willingness to conduct a specific clinical trial. It focuses on technical, operational, and regulatory capacity as well as historical performance data.

Does the site have access to the required patient population?
Is the site equipped with the right infrastructure and equipment?
Do investigators have therapeutic experience relevant to the protocol?

Feasibility helps sponsors and CROs narrow down which sites are theoretically capable of performing the study based on protocol requirements.

Key Activities in Site Feasibility:

Dissemination of feasibility questionnaires
Site responses including investigator CVs, enrollment projections, and staff qualifications
Telephonic or in-person feasibility visits (Pre-Study Visits)
Historical enrollment performance checks
Assessment of lab certifications and equipment readiness

These steps provide quantitative and qualitative inputs for ranking sites during the selection phase.

What Is Site Selection?

Site selection is the final decision-making step to choose

which sites will participate in the clinical trial, based on feasibility results and strategic criteria.

Includes evaluation of operational capability and prior GCP compliance
Considers site responsiveness, contract negotiation history, and regulatory familiarity
Often requires multi-level approvals (e.g., sponsor, CRO, medical monitor)

While feasibility identifies possible sites, site selection finalizes the list of actual study partners.

How Site Feasibility and Site Selection Interact:

Although feasibility precedes selection, the two are intertwined. A well-designed feasibility process leads to faster and more confident site selection. Here’s how:

Feasibility outcomes shape selection criteria (e.g., timeline commitments)
Negative feasibility indicators prompt exclusion or further clarification
Feasibility feedback reveals site-specific risks during selection deliberation

Using platforms like Stability Studies can aid in standardizing feasibility assessments across global trials.

Common Tools Used:

To manage these activities, trial sponsors and CROs typically use:

Feasibility questionnaires and surveys (paper or e-platforms)
Site Information Forms (SIFs)
Feasibility analytics dashboards
Site scorecards and historical performance databases
Contract tracking logs to evaluate responsiveness during past studies

Key Metrics for Feasibility and Selection:

Evaluating feasibility and selection is data-driven. Some key metrics include:

Past enrollment success vs. target
Protocol deviation history
Site initiation timelines
Audit or inspection outcomes
PI workload and competing trials

These data points allow clinical teams to apply a scoring model for objective selection.

Common Challenges and How to Address Them:

Incomplete or inconsistent responses: Use structured digital forms and provide clear guidance.
Over-committed sites: Assess competing study load and site staff availability.
Bias in selection: Use blinded scoring systems for final ranking.
Non-responsive sites: Have a follow-up protocol and backup site list.

Following SOPs for feasibility and site selection ensures uniformity and regulatory readiness.

GCP and Regulatory Considerations:

According to ICH GCP (E6 R2), sponsors must:

Ensure that investigators and sites are qualified by training, experience, and resources
Document site qualification and justification for selection
Maintain clear records in the Trial Master File (TMF)

Regulatory bodies such as the EMA may audit site selection rationale during inspections.

Best Practices for Harmonizing Feasibility and Selection:

Use unified templates for feasibility across countries and CROs
Maintain a historical site database with key performance indicators (KPIs)
Schedule early engagement calls with sites to build rapport
Pre-identify backup sites in case primary ones fail selection
Integrate feasibility scoring into selection presentations for leadership buy-in

Conclusion:

Site feasibility and site selection are complementary processes that determine the quality and efficiency of clinical trial execution. By using structured tools, clear metrics, and collaborative engagement, clinical teams can ensure that selected sites meet both operational and regulatory expectations. Aligning these activities with GMP audit practices and using standardized SOPs supports transparency and long-term success.